Effects of sulglycotide on inflammation and epithelial cell turnover in active Helicobacter pylori+ chronic gastritis. A pilot study.
The effects of Sulglycotide were evaluated in a pilot study of active H. pylori+ atrophic gastritis. Ten informed patients (mean age 51 +/- 13 years) entered a double-blind study. Five received Sulglycotide 400 mg three times a day for one year, the other 5, placebo. At 0, 30, 90, 270, and 360 days of treatment, patients underwent endoscopic examinations with multiple biopsies. Morphometric studies (number of inflammatory cells and percent gland volume), morphologic studies (according to the Sydney system), and flow cytofluorimetry were performed in all cases. Compared to findings in the placebo group, patients treated with Sulglycotide showed a reduced number of inflammatory cells and an increase in gland volume 120 days after treatment. While the difference was not statistically significant, the trend was confirmed by the morphologic patterns. Flow cytofluorimetry revealed an increase in the percentage of cells in the G2 phase (full maturation) and a parallel drop in the S phase (premitotic synthesis) in the Sulglycotide group only in the first three months. These data would appear to indicate an acceleration of gastric epithelial cell maturation and a decrease in the inflammatory infiltrate under the effect of Sulglycotide.
Bazuro
G E
GE
Digestive Diseases and Nutrition Department, S Filippo Neri Hospital, Rome, Italy.
Dezi
A
A
Pallotta
L
L
Masci
P
P
Teodori
L
L
Trinca
M L
ML
Koch
M
M
Capurso
L
L
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002453:Cell Cycle; D002908:Chronic Disease; D004311:Double-Blind Method; D004848:Epithelium / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D005753:Gastric Mucosa / Q000473:pathology; D005757:Gastritis, Atrophic / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology*; D016481:Helicobacter Infections / Q000150:complications*; D016480:Helicobacter pylori; D006801:Humans; D007249:Inflammation / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012795:Sialoglycoproteins / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D012795:Sialoglycoproteins; C009354:sulglicotide